Roche launches new type A haemophilia drug Hemlibra (emicizumab)

recently,, a Japanese drug http://
maker controlled by Roche, announced that its wholly-owned subsidiarycompany in Taiwan, http://,, had
launched the new drug, http://, to the marketAbout HemlibraHemlibra was approved by the Taiwan Food andMedicines(http://Regulatory Authority (T
FDA(http://at the end of October this year, and can be injected weekly, every 2 weeks, every 4 weeks under the skin for patients with type A haemophiliacs who do not produce coagulation factor VIII inhibitors in the body to prevent haemorrhagic episodes The TFDA also approved Hemlibra's 2-weekly, 4-week-long administration for patients with type A hemophilia who have developed coagulation factor VIII inhibitors in the body 　　Hemlibra is a bispecific monoclonal antibody that combines the two proteins necessary to activate the natural coagulation cascade reaction and restore the natural clotting process , the coagulation factors IXa and X -- to restore the clotting process in patients with type A haemophiliacs In clinical studies, Hemlibra has been shown to significantly reduce bleeding events and improve machine function 　　Hemlibra is developed by Chinese and foreign pharmaceutical companies, and is currently developed by Sino-foreign pharmaceuticals, Roche and its gene Tektronix Hemlibra was developed to help overcome the current clinical challenges facing the hemophilia Type A population: the existing drug (http:// the duration of the drug effect is short, the production of VIII inhibitors, and the frequent infusion demand 　　Hemlibra was first approved by the U.S FDA in November 2017 as a routine preventive drug for patients with type A haemophiliac type A who have developed coagulation factor VIII inhibitors in the body to prevent or reduce the frequency of bleeding events